Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

Impact · against what's priced in

NeOnc (NTHI) is entering a high-volatility period with multiple upcoming clinical catalysts. The combination of full enrollment for the NEO100 Phase 2a study, international regulatory clearance for NEO212 in Abu Dhabi, and aggressive insider buying by the CEO suggests a positive shift in the company's near-term risk-reward profile.

NTHI+0.60

No priced-in read yet